The correlation of long non-coding RNAs IFNG-AS1 and ZEB2-AS1 with IFN-γ and ZEB-2 expression in PBMCs and clinical features of patients with coronary artery disease.
Coronary Artery Disease
IFNG-AS1
Long non-coding RNA
PBMC
ZEB2-AS1
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
18
09
2021
accepted:
19
01
2022
pubmed:
8
4
2022
medline:
10
6
2022
entrez:
7
4
2022
Statut:
ppublish
Résumé
Aberrant expression of long non-coding RNAs (lncRNAs) can contribute to the pathogenesis of coronary artery disease (CAD). In this study, we aimed to evaluate the expression of lncRNA interferon γ-antisense 1 (IFNG-AS1), zinc finger E-box binding homeobox 2 antisense RNA 1 (ZEB2-AS1), and their direct target genes (IFN-γ and ZEB2, respectively) in peripheral blood mononuclear cell (PBMC) from CAD and healthy individuals. We recruited 40 CAD patients and 40 healthy individuals. After doing some bioinformatics analyses, the expressions of IFNG-AS1/ ZEB2-AS1 lncRNAs and IFN-γ/ ZEB2 in PBMCs were measured using quantitative real-time PCR. The possible correlation between the putative lncRNAs and disease severity was also assessed. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive role of lncRNAs as diagnostic biomarkers in CAD patients. The expressions of IFNG-AS1 lncRNA as well as IFN-γ and ZEB2 genes were significantly reduced in CAD patients compared to healthy subjects. In contrast, the expression of ZEB2-AS1 was up-regulated in these patients. Linear regression analysis unveiled that there is a positive correlation between the expression of IFNG-AS1 and IFN-γ, also similarly, ZEB2-AS1 and ZEB2 in PBMCs of subjects. Moreover, the expression of IFNG-AS1 and ZEB2-AS1 correlated with the Gensini score. The area under the ROC curves ranged from 0.633-0.742 for ZEB2-AS1/ZEB2 and IFNG-AS1/IFN-γ, respectively. Our results indicated that the dysregulation of IFNG-AS1/IFN-γ and ZEB2-AS1/ZEB2 in PBMCs of CAD patients may be involved in CAD pathogenesis.
Sections du résumé
BACKGROUND
BACKGROUND
Aberrant expression of long non-coding RNAs (lncRNAs) can contribute to the pathogenesis of coronary artery disease (CAD). In this study, we aimed to evaluate the expression of lncRNA interferon γ-antisense 1 (IFNG-AS1), zinc finger E-box binding homeobox 2 antisense RNA 1 (ZEB2-AS1), and their direct target genes (IFN-γ and ZEB2, respectively) in peripheral blood mononuclear cell (PBMC) from CAD and healthy individuals.
METHODS AND RESULTS
RESULTS
We recruited 40 CAD patients and 40 healthy individuals. After doing some bioinformatics analyses, the expressions of IFNG-AS1/ ZEB2-AS1 lncRNAs and IFN-γ/ ZEB2 in PBMCs were measured using quantitative real-time PCR. The possible correlation between the putative lncRNAs and disease severity was also assessed. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive role of lncRNAs as diagnostic biomarkers in CAD patients. The expressions of IFNG-AS1 lncRNA as well as IFN-γ and ZEB2 genes were significantly reduced in CAD patients compared to healthy subjects. In contrast, the expression of ZEB2-AS1 was up-regulated in these patients. Linear regression analysis unveiled that there is a positive correlation between the expression of IFNG-AS1 and IFN-γ, also similarly, ZEB2-AS1 and ZEB2 in PBMCs of subjects. Moreover, the expression of IFNG-AS1 and ZEB2-AS1 correlated with the Gensini score. The area under the ROC curves ranged from 0.633-0.742 for ZEB2-AS1/ZEB2 and IFNG-AS1/IFN-γ, respectively.
CONCLUSIONS
CONCLUSIONS
Our results indicated that the dysregulation of IFNG-AS1/IFN-γ and ZEB2-AS1/ZEB2 in PBMCs of CAD patients may be involved in CAD pathogenesis.
Identifiants
pubmed: 35389131
doi: 10.1007/s11033-022-07168-9
pii: 10.1007/s11033-022-07168-9
doi:
Substances chimiques
IFNG protein, human
0
RNA, Long Noncoding
0
ZEB2 protein, human
0
Zinc Finger E-box Binding Homeobox 2
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3389-3399Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(16):1685–1695
doi: 10.1056/NEJMra043430
Lee S-E et al (2018) Quantification of coronary atherosclerosis in the assessment of coronary artery disease. Circ Cardiovasc Imaging 11(7):e007562
doi: 10.1161/CIRCIMAGING.117.007562
Malakar AK et al (2019) A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol 234(10):16812–16823
doi: 10.1002/jcp.28350
Kitsios GD et al (2011) Heterogeneity of the phenotypic definition of coronary artery disease and its impact on genetic association studies. Circ Cardiovasc Genet 4(1):58–67
doi: 10.1161/CIRCGENETICS.110.957738
Rafiei A et al (2021) Expression levels of miR-27a, miR-329, ABCA1, and ABCG1 genes in peripheral blood mononuclear cells and their correlation with serum levels of oxidative stress and hs-CRP in the patients with coronary artery disease. IUBMB Life 73(1):223–237
doi: 10.1002/iub.2421
Mohammad-Rezaei M et al (2021) Serum levels of IL-32 in patients with coronary artery disease and its relationship with the serum levels of IL-6 and TNF-alpha. Mol Biol Rep 48(5):4263–4271
doi: 10.1007/s11033-021-06441-7
Leentjens J et al (2018) Trained innate immunity as a novel mechanism linking infection and the development of atherosclerosis. Circ Res 122(5):664–669
doi: 10.1161/CIRCRESAHA.117.312465
McLaren JE, Ramji DP (2009) Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev 20(2):125–135
doi: 10.1016/j.cytogfr.2008.11.003
Voloshyna I, Littlefield MJ, Reiss AB (2014) Atherosclerosis and interferon-γ: new insights and therapeutic targets. Trends Cardiovasc Med 24(1):45–51
doi: 10.1016/j.tcm.2013.06.003
Fernandez D et al (2020) ZEB2 regulates activation and exhaustion programming of CD8+ t cells in atherosclerosis. Arterioscler Thromb Vasc Biol 40(1):258–258
Huang Y, Dai W, Li Y (2019) Potential associations of testosterone/estradiol ratio, leukocyte hTERT expression and PBMC telomerase activity with aging and the presence of coronary artery disease in men. Exp Gerontol 117:38–44
doi: 10.1016/j.exger.2018.08.008
Shan K et al (2016) Role of long non-coding RNA-RNCR3 in atherosclerosis-related vascular dysfunction. Cell Death Dis 7(6):e2248–e2248
doi: 10.1038/cddis.2016.145
Cardona-Monzonís A et al (2020) Non-coding RNAs and coronary artery disease. Non-coding RNAs in Cardiovascular Diseases. Springer, pp 273–285
doi: 10.1007/978-981-15-1671-9_16
Tang N et al (2018) Noncoding RNAs as therapeutic targets in atherosclerosis with diabetes mellitus. Cardiovasc Ther 36(4):12436
doi: 10.1111/1755-5922.12436
Li Y et al (2015) LncRNA ontology: inferring lncRNA functions based on chromatin states and expression patterns. Oncotarget 6(37):39793–39805
doi: 10.18632/oncotarget.5794
Josefs T, Boon RA (2020) The long non-coding road to atherosclerosis. Curr Atheroscler Rep 22(10):55
doi: 10.1007/s11883-020-00872-6
Cremer S et al (2019) Hematopoietic deficiency of the long noncoding RNA MALAT1 promotes atherosclerosis and plaque inflammation. Circulation 139(10):1320–1334
doi: 10.1161/CIRCULATIONAHA.117.029015
Gast M et al (2019) Immune system-mediated atherosclerosis caused by deficiency of long non-coding RNA MALAT1 in ApoE-/-mice. Cardiovasc Res 115(2):302–314
doi: 10.1093/cvr/cvy202
Cai Y et al (2016) Circulating “lncRNA OTTHUMT00000387022” from monocytes as a novel biomarker for coronary artery disease. Cardiovasc Res 112(3):714–724
doi: 10.1093/cvr/cvw022
Lu Y et al (2020) 2017 ACC/AHA blood pressure classification and incident peripheral artery disease: the atherosclerosis risk in communities (ARIC) study. Eur J Prev Cardiol 27(1):51–59
doi: 10.1177/2047487319865378
Gibbons RJ, Smith S, Antman E (2003) American College of Cardiology/American heart association clinical practice guidelines: part I: where do they come from? Circulation 107(23):2979–2986
doi: 10.1161/01.CIR.0000063682.20730.A5
MARK, D.B., et al (1987) Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med 106(6):793–800
doi: 10.7326/0003-4819-106-6-793
Cheng L et al (2019) LncRNA2Target v2 0: a comprehensive database for target genes of lncRNAs in human and mouse. Nucleic Acids Res 47(1):140–144
doi: 10.1093/nar/gky1051
Chen J et al (2021) LncSEA: a platform for long non-coding RNA related sets and enrichment analysis. Nucleic Acids Res 49(D1):D969–D980
doi: 10.1093/nar/gkaa806
Paraskevopoulou MD et al (2016) DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts. Nucleic Acids Res 44(D1):D231–D238
doi: 10.1093/nar/gkv1270
Zhang W et al (2018) SFPEL-LPI: sequence-based feature projection ensemble learning for predicting LncRNA-protein interactions. PLoS Comput Biol 14(12):e1006616
doi: 10.1371/journal.pcbi.1006616
Lin Y et al (2020) RNAInter in 2020: RNA interactome repository with increased coverage and annotation. Nucleic Acids Res 48(D1):D189–D197
doi: 10.1093/nar/gkz804
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods 25(4):402–408
doi: 10.1006/meth.2001.1262
Sanaei MJ et al (2021) Up-regulated CCL18, CCL28 and CXCL13 expression is associated with the risk of gastritis and peptic ulcer disease in helicobacter pylori infection. Am J Med Sci 361(1):43–54
doi: 10.1016/j.amjms.2020.07.030
Libby, P. and G.K. Hansson (2018) Taming immune and inflammatory responses to treat atherosclerosis., American College of Cardiology Foundation Washington, DC.
Hajar R (2017) Risk factors for coronary artery disease: historical perspectives. Heart views: the official journal of the Gulf Heart Association 18(3):109
doi: 10.4103/HEARTVIEWS.HEARTVIEWS_106_17
Moriya J (2019) Critical roles of inflammation in atherosclerosis. J Cardiol 73(1):22–27
doi: 10.1016/j.jjcc.2018.05.010
Aryal B, Rotllan N, Fernández-Hernando C (2014) Noncoding RNAs and atherosclerosis. Curr Atheroscler Rep 16(5):407
doi: 10.1007/s11883-014-0407-3
Pierce JB, Feinberg MW (2020) Long noncoding RNAs in atherosclerosis and vascular injury: pathobiology, biomarkers, and targets for therapy. Arterioscler Thromb Vasc Biol 40(9):2002–2017
doi: 10.1161/ATVBAHA.120.314222
Petermann F et al (2019) The magnitude of IFN-γ responses is fine-tuned by DNA architecture and the non-coding transcript of Ifng-as1. Mol Cell 75(6):1229-1242.e5
doi: 10.1016/j.molcel.2019.06.025
Li H et al (2016) Aberrant expression of long noncoding RNA TMEVPG1 in patients with primary immune thrombocytopenia. Autoimmunity 49(7):496–502
doi: 10.3109/08916934.2016.1167192
Peng H et al (2015) The long noncoding RNA IFNG-AS1 promotes T helper type 1 cells response in patients with Hashimoto’s thyroiditis. Sci Rep 5(1):1–9
Padua, D et al., (2016) A long noncoding RNA signature for ulcerative colitis identifies IFNG-AS1 as an enhancer of inflammation. American Journal of Physiology-Gastrointestinal and Liver Physiology 311(3): 446-457
Luo M et al (2017) IFNA-AS1 regulates CD4+ T cell activation in myasthenia gravis though HLA-DRB1. Clin Immunol 183:121–131
doi: 10.1016/j.clim.2017.08.008
Fallah H et al (2020) IFNG/IFNG-AS1 expression level balance: implications for autism spectrum disorder. Metab Brain Dis 35(2):327–333
doi: 10.1007/s11011-019-00510-4
Yaghoobi H et al (2018) Assessment of expression of interferon γ (IFN-G) gene and its antisense (IFNG-AS1) in breast cancer. World journal of surgical oncology 16(1):1–7
doi: 10.1186/s12957-018-1508-1
Li J, Ley K (2015) Lymphocyte migration into atherosclerotic plaque. Arterioscler Thromb Vasc Biol 35(1):40–49
doi: 10.1161/ATVBAHA.114.303227
Wu X et al (2017) LncRNA ZEB2-AS1 promotes bladder cancer cell proliferation and inhibits apoptosis by regulating miR-27b. Biomed Pharmacother 96:299–304
doi: 10.1016/j.biopha.2017.08.060
Wu F et al (2019) The lncrna ZeB2-as1 is upregulated in gastric cancer and affects cell proliferation and invasion via mir-143-5p/hiF-1α axis. Onco Targets Ther 12:657
doi: 10.2147/OTT.S175521
Cheng Z, Liu L, Li Q (2020) lncRNA ZEB2-AS1 stimulates cardiac hypertrophy by downregulating PTEN. Exp Ther Med 20(5):1–1
doi: 10.3892/etm.2020.9220
Lan T et al (2016) Downregulation of ZEB2-AS1 decreased tumor growth and metastasis in hepatocellular carcinoma. Mol Med Rep 14(5):4606–4612
doi: 10.3892/mmr.2016.5836
Gladka MM et al (2021) Cardiomyocytes stimulate angiogenesis after ischemic injury in a ZEB2-dependent manner. Nat Commun 12(1):1–16
doi: 10.1038/s41467-020-20361-3
Ma L et al (2020) Multiple independent mechanisms link gene polymorphisms in the region of ZEB2 with risk of coronary artery disease. Atherosclerosis 311:20–29
doi: 10.1016/j.atherosclerosis.2020.08.013
Scott CL, Omilusik KD (2019) ZEBs: novel players in immune cell development and function. Trends Immunol 40(5):431–446
doi: 10.1016/j.it.2019.03.001
Xu Y, Shao B (2018) Circulating lncRNA IFNG-AS1 expression correlates with increased disease risk, higher disease severity and elevated inflammation in patients with coronary artery disease. J Clin Lab Analysis 32(7):22452
doi: 10.1002/jcla.22452